Seroatlas · Human Serome Atlas

PRAMEF17

PRAME family member 17

Also known as: PRA17_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5VTA0
Gene: PRAMEF17
Ensembl: ENSG00000204479
Chromosome: 1
Canonical length: 474 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable ubiquitin-like ligase-substrate adaptor activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Predicted to be part of Cul2-RING ubiquitin ligase complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

474 residues, UniProt reviewed canonical sequence.

>Q5VTA0|PRAMEF17
     1  MSLQSPSRLL ELAGQSLLRN QFLTIFILDE LPREVFPLMF MEASSMRHFE ALKLMVQAWP
    61  FLRLPLGSLM KTPHLETLQA VLKGLDTLLA QKLRPRRWKL QVLDLRDVDG NFWTIWSGAR
   121  ALSCSPEAMS KRQTVEDYPR TGEHQPLKVF IDLCQKESTL DECLSYLCRW IHYRRGLVHL
   181  CCNKVQNYSM PTSSFRNLLK RVYPDSIQEL EIKRKCSLNK TGKFAPYLSQ MSNLRKLFLA
   241  FGYDDELYVS GQQQFVPDLD CPFLCLYYPQ MLYIRKISNI KEHLEHLLRC LKNPLGTFIF
   301  CHAYLADQDM ECLSQYPSLS QLKELHLIHI LMWTTNLEPL GALLEKVAAT LEILTLKDCQ
   361  IQDSQLRVLL PALSRCSQLT TFYFRGNETS TNALKDLLCH TGGLSKLGLE LYPAPLECLD
   421  NRGHVNWEIL APIRAELMCT LREVRQPKRI FFGPIPCPSC GSWPSEKVDF HLCS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAMEF17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 0 nTPM

Expression across tissuesHPA

Tissue

adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM
blood vessel: 0 nTPM

Single-cell type

adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM
astrocytes: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

choroid plexus: 0.3 nTPM
hypothalamus: 0.3 nTPM
white matter: 0.3 nTPM
amygdala: 0.2 nTPM
basal ganglia: 0.2 nTPM
cerebral cortex: 0.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.95
gnomAD pLI: 0
gnomAD missense Z: -0.43

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ubiquitin-like ligase-substrate adaptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAMEF17 as an antibody target. Whether an autoantibody or antibody against PRAMEF17 could matter depends on whether native PRAMEF17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAMEF17 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRAMEF17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...